Modern WisdomWhat Embryo Selection Means for Humanity - Dr Jonathan Anomaly
CHAPTERS
- 0:00 – 3:58
Embryo selection vs gene editing: what the tech actually does
Jonathan explains why embryo selection triggers backlash: it’s new, poorly understood, and often confused with gene editing. He clarifies that polygenic embryo selection doesn’t “tinker” with genomes—it surfaces information about natural variation across IVF embryos so parents can choose among them.
- •Public skepticism stems from novelty and confusion with gene editing
- •IVF already involves selection (often via embryo morphology)
- •PGT-A (aneuploidy) and PGT-M (single-gene disorders) are established; polygenic screening extends this
- •Core claim: more information about embryos, not engineered changes
- •Trait selection (especially intelligence) is where discomfort spikes
- 3:58 – 7:25
Disease screening vs trait selection: why intelligence is uniquely taboo
The conversation moves from broad support for disease screening to the cultural unease around selecting for cognitive traits. Jonathan argues the distinction is historically contingent—especially shaped by post-WWII taboos—and that many Asian contexts don’t separate “avoiding disease” from “selecting for advantages.”
- •Survey gap: high support for disease screening, lower support for intelligence screening
- •Post-WWII eugenics legacy drives taboos around genetic explanations of mental traits
- •Mental traits feel closer to identity and moral worth than physical traits
- •Cross-cultural variation: Singapore shows more equal acceptance of disease and trait selection
- •Slippery-slope concerns framed as governance/coercion vs informed individual choice
- 7:25 – 14:30
Inequality and coercion: the rich, subsidies, and the risk of government control
Chris presses on genetic inequality: will wealthy families gain compounding advantages? Jonathan sees the bigger danger as state involvement—mandates, subsidies, or coercive policies—arguing that trying to “fix” inequality via government could increase the risk of coercive eugenics.
- •Assortative mating already concentrates genetic and social advantages
- •Near-term gains are modest (a few IQ points, limited height changes), not a new species divide
- •Subsidies/insurance mandates could broaden access but force dissenters to pay
- •Autonomy conflict: choice to use tech vs choice not to fund it collectively
- •Historical parallels: compulsory vaccination/blood transfusion decisions for children
- 14:30 – 20:44
Making genetics talk less ‘icky’: taboo, signaling, and a more optimistic framing
Chris asks how to communicate behavioral genetics without triggering eugenics alarms. Jonathan argues most people already intuit heritability from family experience; the real barrier is taboo and social signaling. He reframes genetic knowledge as non-deterministic and potentially empowering—another way parents “stack the deck” alongside schools and neighborhoods.
- •People observe heritability in siblings despite shared environments
- •Taboos incentivize public denial of genetic influence (meritocracy narratives)
- •Genetics is probabilistic, not destiny; individuals still have agency
- •Embryo selection as ‘front-loading’ prevention vs later-life interventions
- •Avoiding disability ≠ devaluing disabled people (moral worth vs welfare outcomes)
- 20:44 – 26:56
Inside HeraCyte’s approach: reconstructing embryo genomes from common IVF data
Jonathan outlines the technical innovation behind HeraCyte: using the raw data from standard PGT-A testing plus whole-genome sequencing of parents to infer each embryo’s full genome. He argues this lowers barriers and weakens clinic ‘gatekeeping,’ making polygenic selection broadly accessible.
- •IVF and embryo testing history: from morphology to aneuploidy and monogenic screening
- •Polygenic traits involve thousands of variants; full-genome context matters
- •Key method: combine embryo PGT-A snapshot + parental WGS to reconstruct embryo genome
- •Democratization claim: patients can request raw data and seek independent analysis
- •Ethical frame: informed patient choice vs paternalistic restriction by clinics/doctors
- 26:56 – 33:14
Who gets to choose in IVF: clinic paternalism, probability discomfort, and consistency problems
Chris probes whether parents can already influence embryo choice and how clinics respond to polygenic requests. Jonathan describes uneven clinic openness and a perceived inconsistency: clinics accept probabilistic monogenic risk decisions but resist probabilistic polygenic ones, despite all medicine operating under uncertainty.
- •Parents rarely get deep transparency about embryo selection decisions
- •Some clinics allow patient-directed choices; others insist on morphology-based selection
- •Clinics accept monogenic screening (e.g., Tay-Sachs, sickle cell) but resist polygenic screening
- •BRCA example: monogenic variants explain a small share of total cancer risk; most is polygenic+environment
- •Medicine is inherently probabilistic; resistance often reflects complexity/communication aversion
- 33:14 – 46:44
Can screening companies be trusted? Validation, bad actors, and ancestry portability
Jonathan warns that some polygenic-score vendors are effectively ‘astrology,’ and information asymmetry lets weak products get funded and sold. He lays out how to interrogate a company: score construction, validation strategy, and performance across ancestry groups—illustrating with a couple misled by poor schizophrenia risk scores.
- •Market failure risk: charismatic fundraising can outpace scientific quality
- •Key consumer questions: how were scores built, validated, and audited?
- •Anecdote: another company’s schizophrenia scores misclassified parents; retesting showed low risk
- •Validation approach: within-family/sibling comparisons to avoid confounding
- •Ancestry challenge: European-trained scores often degrade elsewhere; need explicit cross-ancestry reporting
- 46:44 – 51:35
Does the algorithm work in practice? Effect sizes, embryo counts, and trade-offs
Chris asks directly whether the technology works and what benefits look like. Jonathan emphasizes trait-by-trait variability, the importance of family history and embryo number, and realistic expectations—alongside examples showing how parents must balance trade-offs (e.g., cognitive score vs diabetes risk).
- •HeraCyte limits offerings to traits with robust predictive performance
- •Parent reports include simulated embryo distributions (hundreds of recombination simulations)
- •Disease risk reductions can be substantial depending on embryo count and baseline risk
- •Intelligence example: with ~10 embryos, predicted spread ~1 SD; only part of total variation is predictable
- •Real decisions are multi-objective: selecting lower disease risk may sacrifice other predicted advantages
- 51:35 – 1:01:20
Buyer’s remorse and new parental culpability: ‘I chose wrong’
Chris raises the psychological and ethical burden: selection increases perceived responsibility for outcomes. Jonathan concedes greater control can increase culpability, but argues there can also be culpability for refusing available risk reduction in severe family-history cases—while cautioning against making selection socially mandatory.
- •Selection could intensify parental guilt and counterfactual thinking
- •Analogy: new medical interventions (e.g., vaccines) create asymmetry between siblings born before/after
- •Active choice vs omission: under some conditions, not selecting may be morally questionable
- •Risk of cultural pressure and elective IVF growth; concern if norms become policy mandates
- •No clean ‘stop’ mechanism—norms shape how tech is used more than laws do
- 1:01:20 – 1:06:09
Where to draw the line on trait selection: antisocial traits, norms vs law, and the spectrum problem
The discussion shifts to governance: what traits should be off-limits? Jonathan suggests strong social condemnation (and company refusal) for selecting *for* extreme antisocial traits, while acknowledging gray areas because most traits lie on spectra with possible advantages at moderate levels.
- •Proposed red line: selecting for extreme sadism/psychopathy should be refused by companies
- •Uncertainty about criminalization; norms may be more effective than regulation
- •Traits are continuous: ‘too little’ can be harmful (e.g., zero Machiavellianism)
- •Industry dynamics: a ‘space race’ feeling around polygenic embryo selection
- •Ethics requires balancing parental freedom, societal risk, and measurement limitations
- 1:06:09 – 1:13:06
Wrongful life concerns: lawsuits, extreme diseases, and choosing severe harms
Jonathan introduces ‘wrongful life’ legal doctrine and how embryo selection could reshape expectations and liability. They discuss extreme monogenic diseases like Tay-Sachs as paradigmatic cases where selecting *for* severe suffering seems indefensible, and how legal claims might emerge as selection becomes normal.
- •Wrongful life vs wrongful death: claims framed around preventable severe disability
- •Tay-Sachs explained as a devastating protein-folding disorder with short, painful lives
- •Selection changes the moral/legal framing: ‘you could have prevented this’ arguments
- •Company-level refusals suggested for clearly life-destroying traits
- •Ethical tension: prevention vs personhood/identity debates
- 1:13:06 – 1:25:36
Personhood, identity, and the non-identity problem: are we ‘replacing’ people?
The conversation goes philosophical, drawing on Derek Parfit: embryo selection doesn’t improve the *same* person; it changes which person exists. Chris and Jonathan explore how tiny timing changes already alter identity (the ‘different thrust, different child’ intuition), challenging common notions of harm and responsibility.
- •Parfit’s psychological continuity view and its implications for identity across time
- •Non-identity problem: different choices create different people, not ‘better versions’ of the same person
- •Scott Alexander examples: preventing fetal alcohol syndrome can mean conceiving a different child later
- •Clarifying language: ‘reducing risk’ vs ‘selecting a different embryo with lower risk’
- •Personhood gradients: embryo vs fetus vs born child framed via development (brain, circulation, viability)
- 1:25:36 – 1:36:55
Are genes blueprints of our lives? Determinism, meaning, and moral responsibility
Chris asks how merit, luck, and self-conception change when traits become selectable and genetically legible. Jonathan argues scientific reduction can feel disillusioning but also reveal deeper beauty; both discuss how genetic insight can increase compassion while complicating judgments about blame, punishment, and praise.
- •‘Unweaving the rainbow’: science can reduce mystery yet add awe and understanding
- •Genetic influence reframes moral emotions: less retribution, more management/containment for harmful traits
- •Chris’s experience: personality/job fit inferred from genetic testing felt uncomfortably accurate
- •Predisposition vs determinism: genetic knowledge can stabilize identity and preferences
- •Behavioral genetics implications for parenting: less ‘tiger parenting,’ more acceptance of constraints
- 1:36:55 – 1:46:46
Stigma and disability: will embryo screening increase discrimination—or compassion?
Responding to concerns from psychiatric genetics organizations, Jonathan argues genetic explanations often reduce blame and can increase compassion rather than stigma. They compare the logic to other medical advances: preventing conditions doesn’t inherently devalue people living with them.
- •Claim rebuttal: genetic understanding tends to decrease moral blame for psychiatric illness
- •Analogy: banning treatment because it ‘stigmatizes’ is incoherent across medicine
- •Disability community objections often focus on marginal cases (e.g., deafness) rather than severe disease
- •Modern society can accommodate disabilities better than past societies; severity context matters
- •Selection debates hinge on distinguishing welfare improvement from moral worth judgments
- 1:46:46 – 1:53:11
Open sourcing and the marketing race: transparency rules and competitive dynamics
Chris predicts polygenic selection becomes a branding/marketing arms race once methods commoditize. Jonathan agrees much will become public via catalogs and open science, but argues quality still depends on talent, data access, and rigorous validation—and he advocates regulation focused on transparency rather than broad prohibition.
- •Polygenic score catalogs exist but vary widely in quality
- •Risk: well-capitalized firms may market flashy but weak predictors
- •Proposed regulatory ‘red line’: mandatory publication of validation and ancestry performance
- •Innovation-access tradeoff: early adopters fund R&D; later users get cheaper, better tools
- •Geopolitical angle: data access and openness differ (UK biobank vs restricted systems)
- 1:53:11 – 1:58:28
Next 5–10 years: protests, subsidies, geopolitical competition, and Europe’s likely shift
Jonathan forecasts polarized backlash from religious conservatives and parts of the progressive left, alongside rapid uptake in countries willing to subsidize IVF and embrace genetic explanations. He predicts competitive pressures—between nations and neighbors—will erode bans, especially in Europe, as cross-border reproductive travel and consumer demand rise.
- •Expected opposition from both right-wing religious groups and ‘blank slate’ progressives (horseshoe effect)
- •State subsidies for IVF (China/Israel examples) may accelerate normalization and adoption
- •Regional competition dynamics: if one country subsidizes screening, neighbors feel pressure to follow
- •Europe currently restrictive; travel and demand likely push policy reversals over time
- •Cousin marriage/genetic burden in parts of the Middle East as a driver for screening policy
- 1:58:28 – 1:59:26
Where to find Jonathan and learn more about HeraCyte
The episode closes with pointers to HeraCyte’s website and tools that estimate potential gains from screening. Jonathan highlights claimed associations between intelligence scores and broader life outcomes, positioning the product as both health-oriented and life-planning relevant.
- •Website: heracyte.com (named after Hera, goddess of fertility/childbirth)
- •Embryo/IVF calculator and reported expected gains (disease reduction, intelligence)
- •Educational materials and upcoming publications/white papers referenced
- •Claim: intelligence correlates with longevity, health, and cooperation—not just status
- •Closing remarks and outro plug for another episode
